CTRI/2017/02/007837
Not yet recruiting
Phase 4
Multicentric Study onPersistence of Immune Responses of anti-HAV in Children vaccinated with live attenuated Hepatitis A vaccine Biovac-A TM Upto 9 years
Wockhardt Ltd0 sites150 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Wockhardt Ltd
- Enrollment
- 150
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Subjects who were enrolled for the Multi\-centric Trial on Immunogenecity of single dose of Biovac\-ATM Live Attenuated Hepatitis\-A Vaccine (MC/Vaccine/2006/CT\-01\) in 2007 would be considered
- •2\. Subjects who had a baseline anti\-HAV antibody titre \<20mIU/mL in the initial phase of the study (MC/Vaccine/2006/CT\-01\).
- •3\. Written informed consent from the parent or guardian of the subjects.
Exclusion Criteria
- •1\. Subjects who had a baseline anti\-HAV antibody titre \>20mIU/mL(i.e these subjects are considered to be seroprotected prior to vaccination)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 4
Evaluation of immunogenicity of Single dose Live Attenuated Varicella VaccineCTRI/2015/02/005522Wockhardt Ltd
Recruiting
Not Applicable
Multi-institutional study of immunologic response tu surgical stress in patients undergoing pulmonary lobectomyung cancerJPRN-UMIN000021182agoya City University100
Active, not recruiting
Phase 1
Administration of 9valent vaccine against papillomavirus in HIV-positive womeEUCTR2018-000228-33-BECHU Saint-Pierre200
Completed
Not Applicable
A cross-sectional study on the immunological properties of the cow's milk protein hydrolysates and hydrolyzed formulas using blood samples from children with cow's milk allergyCow's milk allergyJPRN-UMIN000046543Kanagawa Chidren's Medical Center10
Active, not recruiting
Not Applicable
A long-term, open follow-up of the immunogenicity and safety of GlaxoSmithKline Biologicals’ HPV-16/18 VLP/AS04 vaccine in healthy female subjects up to 10 years after administration of the first vaccine dose in study HPV-013. - HPV-025 EXT 013For the prevention of high-grade cervical intraepithelial neoplasia (CIN grades 2 and 3) and cervical cancer causally related to human papillomavirus (HPV) types 16 and 18.EUCTR2008-000369-44-DEGlaxoSmithKline Biologicals600